Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

CASI Pharmaceuticals, Inc. - Ordinary Shares (NQ:CASI)

0.2875 -0.5125 (-64.06%)

Streaming Delayed Price Updated: 2:18 PM EST, Feb 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	3,360,163
Open	0.3400
Bid (Size)	0.2874 (400)
Ask (Size)	0.2875 (200)
Prev. Close	0.8000
Today's Range	0.2500 - 0.3749
52wk Range	0.7400 - 3.090
Shares Outstanding	13,378,175
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low? ↗

Today 10:28 EST

CASI stated the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market.

Via Stocktwits

CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel

Today 9:00 EST

Via ACCESS Newswire

Performance

YTD	-65.1%	-65.1%
1 Month	-70.7%	-70.7%
3 Month	-74.6%	-74.6%
6 Month	-87.4%	-87.4%
1 Year	-88.1%	-88.1%

More News

CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)

January 15, 2026

Via ACCESS Newswire

CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia

January 12, 2026

Via ACCESS Newswire

CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements

December 23, 2025

Via ACCESS Newswire

CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing

December 11, 2025

Via ACCESS Newswire

CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting

December 08, 2025

Via ACCESS Newswire

CASI Pharmaceuticals Announces Changes in Board Governance

November 19, 2025

Via ACCESS Newswire

CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results

November 14, 2025

Via ACCESS Newswire

CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ

November 10, 2025

Via ACCESS Newswire

CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

November 04, 2025

Via ACCESS Newswire

CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting

November 03, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 13, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 26, 2025

Via Benzinga

CASI Pharmaceuticals Appoints James Huang to Board of Directors

September 26, 2025

Via ACCESS Newswire

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

September 08, 2025

Via ACCESS Newswire

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 03, 2025

Via ACCESS Newswire

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

September 02, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 29, 2025

Via Benzinga

CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

August 29, 2025

Via ACCESS Newswire

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

August 28, 2025

Via ACCESS Newswire

These stocks are moving in today's pre-market session ↗

August 18, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 18, 2025

Via Benzinga

Why Dayforce Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket ↗

August 18, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 15, 2025

Via Benzinga

Frequently Asked Questions

Is CASI Pharmaceuticals, Inc. - Ordinary Shares publicly traded?

Yes, CASI Pharmaceuticals, Inc. - Ordinary Shares is publicly traded.

What exchange does CASI Pharmaceuticals, Inc. - Ordinary Shares trade on?

CASI Pharmaceuticals, Inc. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for CASI Pharmaceuticals, Inc. - Ordinary Shares?

The ticker symbol for CASI Pharmaceuticals, Inc. - Ordinary Shares is CASI on the Nasdaq Stock Market

What is the current price of CASI Pharmaceuticals, Inc. - Ordinary Shares?

The current price of CASI Pharmaceuticals, Inc. - Ordinary Shares is 0.2875

When was CASI Pharmaceuticals, Inc. - Ordinary Shares last traded?

The last trade of CASI Pharmaceuticals, Inc. - Ordinary Shares was at 02/25/26 02:18 PM ET

What is the market capitalization of CASI Pharmaceuticals, Inc. - Ordinary Shares?

The market capitalization of CASI Pharmaceuticals, Inc. - Ordinary Shares is 3.85M

How many shares of CASI Pharmaceuticals, Inc. - Ordinary Shares are outstanding?

CASI Pharmaceuticals, Inc. - Ordinary Shares has 4M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.